Please login to the form below

Not currently logged in
Email:
Password:

meningitis B

This page shows the latest meningitis B news and features for those working in and with pharma, biotech and healthcare.

GSK's Shingrix sails through FDA advisory committee

GSK's Shingrix sails through FDA advisory committee

EvaluatePharma's latest World Preview report predicts that Shingrix will bring in worldwide product sales of $1.13bn in 2022, adding another blockbuster to GSK's vaccine portfolio alongside meningitis B

Latest news

  • GSK makes case for revaccination with Shingrix GSK makes case for revaccination with Shingrix

    EvaluatePharma's latest World Preview report predicts that Shingrix will bring in worldwide product sales of $1.13bn in 2022, adding another blockbuster to GSK's vaccine portfolio alongside meningitis B

  • Pfizer wins EU approval for MenB vaccine Trumenba Pfizer wins EU approval for MenB vaccine Trumenba

    Pfizer's Trumenba has been approved for the prevention of meningitis B (MenB) in Europe, laying the ground for the first alternative to GlaxoSmithKline's Bexsero, supplies of which have been ... The UK-based Meningitis Research Foundation said it

  • Bexsero halved UK meningitis B cases in first year, says study Bexsero halved UK meningitis B cases in first year, says study

    GlaxoSmithKline's meningitis B vaccine Bexsero has had a dramatic impact on meningitis B cases in the UK, according to a real-world evidence study. ... provides reassurance to parents who have already vaccinated their children or wish to help protect

  • Pfizer posts positive Trumenba vaccine data Pfizer posts positive Trumenba vaccine data

    Pfizer's Trumenba vaccine for meningitis B has shown favourable results in two phase III trials. ... The serogroup B strain accounted for over 30% of around 500 reported cases of meningitis in the US in 2013.

  • US expands recommended use of meningitis B vaccines US expands recommended use of meningitis B vaccines

    The US Advisory Committee on Immunization Practices (ACIP) has said decisions to vaccinate with meningitis B (Men B) vaccines from Pfizer and GlaxoSmithKline in peopled aged 16 to 23 should be ... $130m. . GSK was required to divest the meningitis

More from news
Approximately 5 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Pharma deals during April 2014 Pharma deals during April 2014

    franchise. The icing on the cake is Bexsero for the prevention of meningitis B, which has EU approval and orphan drug designation in the US. Also included in the meningitis “goodie ... training. The Liat Influenza A/B Assay, the first test available

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

04 A Healthy Ambience
Creating a Lifeline to the New Digital User...
03 Health Services
How Pharma Companies Can Survive the Patent Cliff Through Digital Innovation...
From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...

Infographics